Treatment with a topical glucocorticoid, budesonide, reduced the variability of rhinomanometric nasal airway resistance
(2014) In Rhinology 52(1). p.19-24- Abstract
- Background: Previous rhinomanometry studies have shown significant long-term variability of the nasal airway resistance and questioned the clinical validity of rhinomanonnetry. Research question: Could treatment with a topical glucocorticoid, budesonide, influence the long-term variability of active anterior rhinomanometry? Methods: Eight healthy volunteers participated in an unblinded controlled trial without, and later with, nasal budesonide once a day for 5 months. Their nasal airway resistance was measured every two weeks with active anterior rhinomanometry before and after decongestion with xylometazoline hydrochloride. In addition, subjective nasal obstruction was evaluated on a Visual Analogue Scale before each measurement.The... (More)
- Background: Previous rhinomanometry studies have shown significant long-term variability of the nasal airway resistance and questioned the clinical validity of rhinomanonnetry. Research question: Could treatment with a topical glucocorticoid, budesonide, influence the long-term variability of active anterior rhinomanometry? Methods: Eight healthy volunteers participated in an unblinded controlled trial without, and later with, nasal budesonide once a day for 5 months. Their nasal airway resistance was measured every two weeks with active anterior rhinomanometry before and after decongestion with xylometazoline hydrochloride. In addition, subjective nasal obstruction was evaluated on a Visual Analogue Scale before each measurement.The participants had a year earlier been investigated with rhinomanometry every two weeks during 5 months but without budesonide treatment. We compared the variability of nasal airway resistance during the two periods with and without treatment with topical budesonide. Results: Budesonide significantly reduced mean nasal airway resistance and the standard deviation of the mean after decongestion for 6 of 8 participants. The mean reduction of the nasal airway resistance was 40% for the decongested nasal cavity compared to the period without treatment with nasal budesonide. Subjective nasal obstruction assessed by Visual Analogue Scale was reduced in 3 of the 8 participants. Conclusion: The variability of nasal airway resistance was significantly reduced by treatment with topical budesonide for 6 out of 8 healthy volunteers participating in an unblinded repeated 5 month trial where the participants served as their own controls. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4558509
- author
- Thulesius, Helle L. ; Cervin, Anders LU and Jessen, Max
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- rhinomanometry, nasal airway resistance, topical nasal glucocorticoid, xylometazoline, budesonide
- in
- Rhinology
- volume
- 52
- issue
- 1
- pages
- 19 - 24
- publisher
- University Hospital Utrecht
- external identifiers
-
- wos:000336514900004
- scopus:84897890998
- ISSN
- 0300-0729
- language
- English
- LU publication?
- yes
- id
- f0164114-a60a-4b76-90e2-348f743c656a (old id 4558509)
- date added to LUP
- 2016-04-01 13:00:19
- date last changed
- 2025-01-03 03:00:49
@article{f0164114-a60a-4b76-90e2-348f743c656a,
abstract = {{Background: Previous rhinomanometry studies have shown significant long-term variability of the nasal airway resistance and questioned the clinical validity of rhinomanonnetry. Research question: Could treatment with a topical glucocorticoid, budesonide, influence the long-term variability of active anterior rhinomanometry? Methods: Eight healthy volunteers participated in an unblinded controlled trial without, and later with, nasal budesonide once a day for 5 months. Their nasal airway resistance was measured every two weeks with active anterior rhinomanometry before and after decongestion with xylometazoline hydrochloride. In addition, subjective nasal obstruction was evaluated on a Visual Analogue Scale before each measurement.The participants had a year earlier been investigated with rhinomanometry every two weeks during 5 months but without budesonide treatment. We compared the variability of nasal airway resistance during the two periods with and without treatment with topical budesonide. Results: Budesonide significantly reduced mean nasal airway resistance and the standard deviation of the mean after decongestion for 6 of 8 participants. The mean reduction of the nasal airway resistance was 40% for the decongested nasal cavity compared to the period without treatment with nasal budesonide. Subjective nasal obstruction assessed by Visual Analogue Scale was reduced in 3 of the 8 participants. Conclusion: The variability of nasal airway resistance was significantly reduced by treatment with topical budesonide for 6 out of 8 healthy volunteers participating in an unblinded repeated 5 month trial where the participants served as their own controls.}},
author = {{Thulesius, Helle L. and Cervin, Anders and Jessen, Max}},
issn = {{0300-0729}},
keywords = {{rhinomanometry; nasal airway resistance; topical nasal glucocorticoid; xylometazoline; budesonide}},
language = {{eng}},
number = {{1}},
pages = {{19--24}},
publisher = {{University Hospital Utrecht}},
series = {{Rhinology}},
title = {{Treatment with a topical glucocorticoid, budesonide, reduced the variability of rhinomanometric nasal airway resistance}},
volume = {{52}},
year = {{2014}},
}